FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030762071> ?p ?o ?g. }

• W2030762071 endingPage "839" @default.
• W2030762071 startingPage "836" @default.
• W2030762071 abstract "BackgroundThis study assessed the use of bivalirudin as an alternative anticoagulant in patients with heparin-induced thrombocytopenia-thrombotic syndrome (HIT/TS) or antiplatelet factor four-heparin (anti-PF4/H) antibodies undergoing off-pump coronary artery bypass (OPCAB).MethodsIn a prospective, open-label, multicenter study, fifty-one patients with documented anti-PF4/H antibodies and (or) HIT/TS underwent OPCAB with bivalirudin anticoagulation (0.75 mg/kg IV bolus, 1.75 mg/kg/hour infusion). Procedural success (absence of death, Q-wave myocardial infarction, repeat revascularization, and stroke), bleeding, and transfusion at day seven/discharge, thirty days, and twelve weeks were assessed.ResultsThirty-five patients (67%) were included with positive anti-PF4/H antibodies and no thrombocytopenia or thrombosis, eleven patients (22%) had thrombocytopenia, and five patients had clinical HIT/TS (10%). Procedural success at seven days/discharge was achieved in forty-seven patients (92%), while procedural success at thirty days and twelve weeks was 88%. There were no deaths. Chest tube output over the first twenty-four hours was 936 ± 525 mL and twenty-five patients received a red blood cell transfusion during their hospitalization. Two patients required reexploration for persistent postoperative hemorrhage.ConclusionsBivalirudin was an effective alternative anticoagulant for patients with HIT/TS or circulating anti-PF4/H antibodies undergoing OPCAB, with high rates of procedural success and an acceptable incidence of bleeding or transfusions. This study assessed the use of bivalirudin as an alternative anticoagulant in patients with heparin-induced thrombocytopenia-thrombotic syndrome (HIT/TS) or antiplatelet factor four-heparin (anti-PF4/H) antibodies undergoing off-pump coronary artery bypass (OPCAB). In a prospective, open-label, multicenter study, fifty-one patients with documented anti-PF4/H antibodies and (or) HIT/TS underwent OPCAB with bivalirudin anticoagulation (0.75 mg/kg IV bolus, 1.75 mg/kg/hour infusion). Procedural success (absence of death, Q-wave myocardial infarction, repeat revascularization, and stroke), bleeding, and transfusion at day seven/discharge, thirty days, and twelve weeks were assessed. Thirty-five patients (67%) were included with positive anti-PF4/H antibodies and no thrombocytopenia or thrombosis, eleven patients (22%) had thrombocytopenia, and five patients had clinical HIT/TS (10%). Procedural success at seven days/discharge was achieved in forty-seven patients (92%), while procedural success at thirty days and twelve weeks was 88%. There were no deaths. Chest tube output over the first twenty-four hours was 936 ± 525 mL and twenty-five patients received a red blood cell transfusion during their hospitalization. Two patients required reexploration for persistent postoperative hemorrhage. Bivalirudin was an effective alternative anticoagulant for patients with HIT/TS or circulating anti-PF4/H antibodies undergoing OPCAB, with high rates of procedural success and an acceptable incidence of bleeding or transfusions." @default.
• W2030762071 created "2016-06-24" @default.
• W2030762071 creator A5001994412 @default.
• W2030762071 creator A5004815677 @default.
• W2030762071 creator A5016137124 @default.
• W2030762071 creator A5028979236 @default.
• W2030762071 creator A5044448273 @default.
• W2030762071 creator A5056309590 @default.
• W2030762071 creator A5067023495 @default.
• W2030762071 creator A5078154139 @default.
• W2030762071 date "2007-09-01" @default.
• W2030762071 modified "2023-10-15" @default.
• W2030762071 title "Off-Pump Coronary Artery Bypass With Bivalirudin for Patients With Heparin-Induced Thrombocytopenia or Antiplatelet Factor Four/Heparin Antibodies" @default.
• W2030762071 cites W1989314872 @default.
• W2030762071 cites W1990012950 @default.
• W2030762071 cites W1996805811 @default.
• W2030762071 cites W2014731265 @default.
• W2030762071 cites W2026561579 @default.
• W2030762071 cites W2049376452 @default.
• W2030762071 cites W2071283345 @default.
• W2030762071 cites W2088764048 @default.
• W2030762071 cites W2150983644 @default.
• W2030762071 cites W2340070814 @default.
• W2030762071 cites W4256164684 @default.
• W2030762071 doi "https://doi.org/10.1016/j.athoracsur.2007.04.007" @default.
• W2030762071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17720385" @default.
• W2030762071 hasPublicationYear "2007" @default.
• W2030762071 type Work @default.
• W2030762071 sameAs 2030762071 @default.
• W2030762071 citedByCount "78" @default.
• W2030762071 countsByYear W20307620712012 @default.
• W2030762071 countsByYear W20307620712013 @default.
• W2030762071 countsByYear W20307620712014 @default.
• W2030762071 countsByYear W20307620712015 @default.
• W2030762071 countsByYear W20307620712016 @default.
• W2030762071 countsByYear W20307620712017 @default.
• W2030762071 countsByYear W20307620712018 @default.
• W2030762071 countsByYear W20307620712019 @default.
• W2030762071 countsByYear W20307620712020 @default.
• W2030762071 countsByYear W20307620712021 @default.
• W2030762071 countsByYear W20307620712022 @default.
• W2030762071 countsByYear W20307620712023 @default.
• W2030762071 crossrefType "journal-article" @default.
• W2030762071 hasAuthorship W2030762071A5001994412 @default.
• W2030762071 hasAuthorship W2030762071A5004815677 @default.
• W2030762071 hasAuthorship W2030762071A5016137124 @default.
• W2030762071 hasAuthorship W2030762071A5028979236 @default.
• W2030762071 hasAuthorship W2030762071A5044448273 @default.
• W2030762071 hasAuthorship W2030762071A5056309590 @default.
• W2030762071 hasAuthorship W2030762071A5067023495 @default.
• W2030762071 hasAuthorship W2030762071A5078154139 @default.
• W2030762071 hasBestOaLocation W20307620711 @default.
• W2030762071 hasConcept C126322002 @default.
• W2030762071 hasConcept C127413603 @default.
• W2030762071 hasConcept C141071460 @default.
• W2030762071 hasConcept C159973064 @default.
• W2030762071 hasConcept C2776301958 @default.
• W2030762071 hasConcept C2776472838 @default.
• W2030762071 hasConcept C2776710957 @default.
• W2030762071 hasConcept C2777292125 @default.
• W2030762071 hasConcept C2777557582 @default.
• W2030762071 hasConcept C2777565915 @default.
• W2030762071 hasConcept C2778205648 @default.
• W2030762071 hasConcept C2778810321 @default.
• W2030762071 hasConcept C2779026020 @default.
• W2030762071 hasConcept C2779161974 @default.
• W2030762071 hasConcept C2779612170 @default.
• W2030762071 hasConcept C2780400711 @default.
• W2030762071 hasConcept C2780645631 @default.
• W2030762071 hasConcept C2780868729 @default.
• W2030762071 hasConcept C42219234 @default.
• W2030762071 hasConcept C500558357 @default.
• W2030762071 hasConcept C71924100 @default.
• W2030762071 hasConcept C78519656 @default.
• W2030762071 hasConcept C89560881 @default.
• W2030762071 hasConceptScore W2030762071C126322002 @default.
• W2030762071 hasConceptScore W2030762071C127413603 @default.
• W2030762071 hasConceptScore W2030762071C141071460 @default.
• W2030762071 hasConceptScore W2030762071C159973064 @default.
• W2030762071 hasConceptScore W2030762071C2776301958 @default.
• W2030762071 hasConceptScore W2030762071C2776472838 @default.
• W2030762071 hasConceptScore W2030762071C2776710957 @default.
• W2030762071 hasConceptScore W2030762071C2777292125 @default.
• W2030762071 hasConceptScore W2030762071C2777557582 @default.
• W2030762071 hasConceptScore W2030762071C2777565915 @default.
• W2030762071 hasConceptScore W2030762071C2778205648 @default.
• W2030762071 hasConceptScore W2030762071C2778810321 @default.
• W2030762071 hasConceptScore W2030762071C2779026020 @default.
• W2030762071 hasConceptScore W2030762071C2779161974 @default.
• W2030762071 hasConceptScore W2030762071C2779612170 @default.
• W2030762071 hasConceptScore W2030762071C2780400711 @default.
• W2030762071 hasConceptScore W2030762071C2780645631 @default.
• W2030762071 hasConceptScore W2030762071C2780868729 @default.
• W2030762071 hasConceptScore W2030762071C42219234 @default.
• W2030762071 hasConceptScore W2030762071C500558357 @default.
• W2030762071 hasConceptScore W2030762071C71924100 @default.
• W2030762071 hasConceptScore W2030762071C78519656 @default.
• W2030762071 hasConceptScore W2030762071C89560881 @default.

• next